These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15386731)

  • 1. Antihypertensive treatment is associated with improved left ventricular geometry: the Rotterdam Study.
    Bleumink GS; Deinum J; Mosterd A; Witteman JC; Hofman A; Stricker BH
    Pharmacoepidemiol Drug Saf; 2004 Oct; 13(10):703-9. PubMed ID: 15386731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in left ventricular geometry during antihypertensive treatment.
    Salvetti M; Paini A; Bertacchini F; Stassaldi D; Aggiusti C; Agabiti Rosei C; Bassetti D; Agabiti-Rosei E; Muiesan ML
    Pharmacol Res; 2018 Aug; 134():193-199. PubMed ID: 29959031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study.
    Palmieri V; Bella JN; Gerdts E; Wachtell K; Papademetriou V; Nieminen MS; Dahlöf B; Devereux RB
    Am J Hypertens; 2008 Jun; 21(6):701-7. PubMed ID: 18437127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence with treatment in newly treated middle-aged patients with essential hypertension.
    Perreault S; Lamarre D; Blais L; Dragomir A; Berbiche D; Lalonde L; Laurier C; St-Maurice F; Collin J
    Ann Pharmacother; 2005 Sep; 39(9):1401-8. PubMed ID: 16076920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Left ventricular hypertrophy and cardiovascular risk in hypertension].
    Amabile G
    Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):86-90. PubMed ID: 9772934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of left ventricular hypertrophy: do antihypertensive classes differ?
    Sheridan DJ
    J Hypertens Suppl; 2000 Jul; 18(3):S21-7. PubMed ID: 10952084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
    Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
    Smebye ML; Iversen EK; Høieggen A; Flaa A; Os I; Kjeldsen SE; Olsen MH; Chattopadhyay A; Hille DA; Lyle PA; Devereux RB; Dahlöf B
    Am J Cardiol; 2007 Sep; 100(5):855-9. PubMed ID: 17719333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversibility of left ventricular hypertrophy.
    Cruickshank JM
    Blood Press Suppl; 1992; 1():32-3; discussion 33-4. PubMed ID: 1343270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regression of left ventricular hypertrophy in hypertensive heart disease].
    Hennersdorf MG; Schannwell CM; Schwartzkopff B; Strauer BE
    Herz; 2003 Dec; 28(8):764-78. PubMed ID: 14689112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients.
    Verdecchia P; Angeli F; Pittavini L; Gattobigio R; Benemio G; Porcellati C
    Ital Heart J; 2004 Jul; 5(7):505-10. PubMed ID: 15487267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
    Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
    J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH; Alfayoumi F
    Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and reduction of left ventricular hypertrophy in the elderly.
    Lavie CJ; Milani RV; Messerli FH
    Clin Geriatr Med; 1996 Feb; 12(1):57-68. PubMed ID: 8653663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.